Clinical Trials Directory

Trials / Conditions / Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified

Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified

8 registered clinical trials studyying Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified — 1 currently recruiting.

StatusTrialSponsorPhase
CompletedModified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refr
NCT04074746
M.D. Anderson Cancer CenterPhase 1 / Phase 2
WithdrawnBrentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
NCT04795869
Northwestern UniversityPhase 2
Active Not RecruitingPembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
NCT03598998
City of Hope Medical CenterPhase 1 / Phase 2
Active Not RecruitingStudy of Pembrolizumab (MK-3475) in Combination With Romidepsin
NCT03278782
M.D. Anderson Cancer CenterPhase 1 / Phase 2
TerminatedNivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
NCT03075553
Mayo ClinicPhase 2
RecruitingA Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemi
NCT03017820
Mayo ClinicPhase 1
Active Not RecruitingDurvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripher
NCT03011814
City of Hope Medical CenterPhase 1 / Phase 2
CompletedRomidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Periph
NCT01590732
M.D. Anderson Cancer CenterPhase 1